Elevation Oncology, Inc.: management transactions · United States · SEC (Form 4)

About Elevation Oncology, Inc.

Elevation Oncology, Inc. is a United States-based biopharmaceutical company that was listed on the Nasdaq market under the ticker ELEV. The company was founded in 2019 under the former name 14ner Oncology, Inc. and later renamed Elevation Oncology, Inc. Its business has been built around the discovery and development of selective cancer therapies for patients with solid tumors that have significant unmet medical needs. According to its SEC filings, the company’s principal executive offices are in Boston, Massachusetts, and it does not maintain a traditional operating corporate headquarters footprint, which is consistent with a capital-efficient biotech structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025002397/elev-20241231x10k.htm?utm_source=openai)) From a strategic standpoint, Elevation Oncology positioned itself as an oncology precision-medicine company with a focus on antibody-drug conjugates, or ADCs. Its pipeline historically included EO-3021, a Claudin 18.2 ADC, and EO-1022, a HER3-targeted ADC. The company’s public disclosures in 2025 show a sharp narrowing of the pipeline: in March 2025, it announced it was discontinuing EO-3021 and evaluating strategic alternatives to maximize shareholder value, and in June 2025 it terminated the related CSPC license agreement. At the same time, the company highlighted EO-1022 as its lead remaining program, describing it as a potentially differentiated HER3 ADC for HER3-expressing solid tumors, with an IND filing expected in 2026. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025007801/elev-20250331x10q.htm?utm_source=openai)) For investors, the company’s competitive position was that of an early-stage biotech operating in a highly contested oncology landscape. Its appeal came from targeted cancer biology, biomarker-driven patient selection, and the broader market interest in ADC platforms. However, as with most development-stage oncology names, the investment case depended heavily on preclinical and clinical de-risking, regulatory progress, and access to capital rather than current commercial revenues. In other words, the stock was driven primarily by pipeline execution and event risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000155837025002397/elev-20241231x10k.htm?utm_source=openai)) The most important recent corporate event was the merger agreement announced on June 8, 2025, under which Concentra Biosciences agreed to acquire Elevation Oncology for $0.36 in cash per share plus a contingent value right. Subsequent SEC filings and Form 4 insider-transaction documents in July 2025 reflect the merger process and related equity disposition mechanics. This is a decisive development for any investor analysis, because it effectively shifted the company from a standalone Nasdaq-listed oncology developer into a transaction-driven situation with a defined exit framework. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1783032/000110465925057620/tm2517439d1_8k.htm?utm_source=openai))